Introduced
by
To impose a new mandate that manufacturers of prescription drugs file detailed reports on the costs associated with developing drugs whose cost or cost increases exceed certain price levels.
Referred to the Committee on Health Policy
Reported without amendment
With the recommendation that the substitute (H-1) be adopted and that the bill then pass.
Amendment offered
by
To apply the same or similar rules to a "biological drug product or biosimilar drug product".
The amendment passed by voice vote
Passed in the House 100 to 7 (details)
Referred to the Committee on Health Policy and Human Services
